# NCT06437509 (NCT06437509)

> A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06437509
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Conditions: Extensive-stage Small-cell Lung Cancer
- Interventions: BL-B01D1; PD-1 monoclonal antibody
- Enrollment: 66
- Primary outcome: Objective Response Rate (ORR)
- Primary outcome: Recommended Phase II Dose (RP2D)

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06437509